National HIV CurriculumLogo
Common TitleMK-1439A-028
Official Title Phase IIb, Double-Blinded, Multicenter, Randomized Study to Assess the Effect on Central Nervous System (CNS) Toxicity of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Subjects.
Phase Phase IIB
ClinicalTrials.gov NCT02652260
Treatments
Doravirine

Doravirine

Tradename:PifeltroOther Names:DORClass:Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
Funding
IndustryMerck

Share by e-mail

The Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS) provided financial support for this website. The award provided 100% of total costs and totaled $1,175,136. The contents are those of the author. They may not reflect the policies of HRSA, HHS, or the U.S. Government.

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.